Bisphosphonates

Osteoporosis: Treatment

By NWHN Staff | Nov 2, 2017 | Comments Off on Osteoporosis: Treatment

Women want to know when it is appropriate to take a drug for osteoporosis, and which treatments are safe and effective. History has shown that preventing loss of bone mineral density in women who are otherwise at low risk of experiencing a fracture is dangerous.

What You Should Know About Tymlos (Abaloparatide) for Osteoporosis

By Caila Brander | May 20, 2017 | Comments Off on What You Should Know About Tymlos (Abaloparatide) for Osteoporosis

The National Women’s Health Network believes women have a right to know the potential benefits and risks of osteoporosis treatment, so we took a firsthand look at the evidence. We’ve compiled a quick fact sheet about the drug so you can get the unbiased truth.

Do Bone Drugs Lose Their Effectiveness?

By Shaniqua Seth | Nov 30, 2016 | Comments Off on Do Bone Drugs Lose Their Effectiveness?

I have been treated with Aclasta for the last four years. My doctor wants to switch me to Prolia. He told me research has shown that using the same drug reduces its effectiveness. Is it true that Aclasta may lose effectiveness over extended use?

Letter to the Washington Post: Why Some Women Are Afraid to Treat Osteoporosis

By Cindy Pearson | Oct 24, 2016 | Comments Off on Letter to the Washington Post: Why Some Women Are Afraid to Treat Osteoporosis

Women continue to experience gaps in healthcare access for a variety of issues, and we advocate for changes in the healthcare system that would remedy this. Bisphosphonate use, however, is one time when less really is more.

Reconsidering Reclast

By Shaniqua Seth | Aug 11, 2016 | Comments Off on Reconsidering Reclast

Reclast is one of eight FDA approved bisphosphonates. Bisphosphonates are a type of drug commonly used for osteoporosis treatment and prevention.

Are “Scary Bone Drugs” Necessary to Prevent Fractures?

By NWHN Staff | Jul 13, 2016 | Comments Off on Are “Scary Bone Drugs” Necessary to Prevent Fractures?

The NWHN acknowledges the overbearing influence pharmaceutical companies have on doctors and patients. This issue arises for those diagnosed with high bone fracture risk. Women are specifically targeted since they’re five times more likely to be diagnosed than men.

More Support for Osteoporosis Prevention – Not Osteoporosis Drugs

By NWHN Staff | Mar 1, 2016 | Comments Off on More Support for Osteoporosis Prevention – Not Osteoporosis Drugs

Bisphosphonate use for prevention has declined in recent years – and that’s a victory! But we’re concerned that a recent article in the Wall Street Journal with the misleading title “More Support for Osteoporosis Drugs: The benefits of bisphosphonates outweigh the risks for many patients” encourages the overuse of drugs that have not proven safe or effective as a preventive measure for women.

Osteoporosis: Better Screening, Treatment Policy Issues

By NWHN Staff | Aug 14, 2015 | Comments Off on Osteoporosis: Better Screening, Treatment Policy Issues

The way we screen and treat osteoporosis is still deeply flawed. The NWHN thinks women deserve better, and we’re fighting to make that vision a reality.